Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="As scientists gear up for what could be one of the biggest market booms this side of the COVID inoculation roll-out, we look at some challenges and opportunities facing the oligonucleotide industry today."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="As scientists gear up for what could be one of the biggest market booms this side of the COVID inoculation roll-out, we look at some challenges and opportunities facing the oligonucleotide industry today."> <meta property="og:title" content="Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine"> <meta name="twitter:description" content="As scientists gear up for what could be one of the biggest market booms this side of the COVID inoculation roll-out, we look at some challenges and opportunities facing the oligonucleotide industry today."> <meta name="twitter:title" content="Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/optimising-oligonucleotide-therapies-efficacy-targetability-and-precision-medicine"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Oligonucleotide-Precision-Medicine-scaled-e1646216129168.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Oligonucleotide-Precision-Medicine-scaled-e1646216129168.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/optimising-oligonucleotide-therapies-efficacy-targetability-and-precision-medicine"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Oligo Chemistry | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine </h1> <div class="byline"> Edited by Tia Byer | 03 March 2022 </div> <div class="abstract"> With efficacy, safety, and targetability being the top three challenges facing the nucleotide-based therapeutic industry today, will oligo-based therapies fulfil their potential as a clinical modality? </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Oligonucleotide-Precision-Medicine-scaled-e1646216129168.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap">  <p>Oligonucleotides are nucleotide-based therapeutics designed to hybridise DNA and RNA sequences. They treat diseases such as cancer, respiratory conditions, and neuromuscular disorders, and work by inhibiting the expression of disease-causing genes. Currently, there are 135 oligo treatments in the pre-clinical stage and the industry is expected to reach 8.2 billion USD by 2024. As scientists gear up for what could be one of the biggest market booms this side of the COVID inoculation roll-out, we look at some challenges and opportunities facing the oligonucleotide industry today.  </p>   <h2 id="h-oligonucleotide-therapies-what-are-they-and-how-do-they-work">Oligonucleotide Therapies: What are They? And How do They Work?</h2>   <p>There are at least five key classes of oligonucleotide therapies. Antisense Oligonucleotides (ASOs) and siRNA target cellular RNA by Watson-Crick base-pairing. In contrast, CRISPR approaches target genomic DNA by Watson-Crick base-pairing. Therapeutic mRNA are translated to proteins and structured Nucleic Acids can interact with proteins through 3-dimensional shape recognition. So far, these applications have revolutionised the study of gene and protein expression.  </p>   <p><strong>Antisense Oligonucleotides:</strong> Antisense oligonucleotides or ASOs are single-stranded sequence-specific therapies that target the source of pathogenesis. ASOs bind to their target RNA sequence and depending on the chemical design employed, can cause gene knockdown, modulate mRNA splicing, block translation or promote mRNA editing. ASOs target the RNA before the toxic protein is formed or if the RNA itself is toxic and are potentially more efficient than therapies targeting the toxic protein <em>after</em> it is formed. Unlike small interfering RNA, ASOs can target RNA in the nucleus and the cytoplasm. However <em>effective </em>targeting is not always easy. Chemical modifications are used to increase the metabolic stability of ASOs, as unmodified oligonucleotides are susceptible to degradation by nucleases in biological systems. Targeted delivery is achieved by using ligands that target cell-surface receptors in cells and tissues of interest.</p>   <p><strong>siRNA: </strong>Like ASOs, siRNA also bind to their target RNA by Watson-Crick base pairing. However, double stranded siRNA are first loaded into the RISC complex which scans the mRNA space for the cognate match followed by cleavage of the targeted mRNA. SiRNA are also heavily chemically modified to enhance their metabolic stability, potency, and reduce side-effects. In general, targeting strategies that work for ASOs are also applicable for delivery of siRNA. Because siRNA therapies employ a double-stranded approach, they can be more difficult to get into cells than ASOs in the absence of targeting ligands. Nevertheless, fewer molecules in the cell are required for effective therapy.</p>   <p><strong>CRISPR:</strong> The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system is a powerful form of gene editing. CRISPRs consist of a mutated intronic region and antisense oligonucleotide to form a mediated correction of mRNA splicing. CRISPR can be used to treat rare and progressive diseases such as Transthyretin amyloidosis (TTR). In particular, biotechnology company Intellia Therapeutics have successfully used lipid nanoparticles containing genetic instructions for CRISPR to target TTR in the liver.</p>   <p><strong>mRNA: </strong>Therapeutic mRNA are translated into therapeutic proteins. Like other classes of oligonucleotide therapeutics, mRNA can also be chemically modified to enhance their effectiveness. However, unlike ASOs and siRNA, mRNA must be delivered using nanoparticles that help with cellular entry and endosomal release. Once in the cytoplasm, mRNA are translated to therapeutic proteins. mRNA based vaccines delivered using lipid nanoparticles have proved effective against COVID-19 and are also being tested against other viral infections and cancer.</p>   <p><strong>Nucleic Acid: </strong>Nucleic acids such as aptamers and immunomodulatory oligonucleotides interact with proteins via the formation of three-dimensional secondary structures. Nucleic acid-based therapies act as both antagonists and agonists for specific proteins. However, nucleic acid-based drug therapies are not without their challenges. Detection of any exogenous nucleic acids can trigger inflammatory responses. This occurs via interactions with pattern recognition receptors, such as membrane-bound Toll-like receptors or cytosolic RIG-I family receptors.</p>   <h2>Challenges in Pre-Clinical Development: Efficacy, Safety, and Delivery</h2>   <p><strong>Safety:</strong> Oligonucleotide therapeutics are relatively larger, meaning their ability to penetrate cell membranes and hit target sites creates a challenge for effective delivery. In addition to this, they are negatively charged and unable to passively diffuse across phospholipid bilayers that make up cell membranes, particularly the blood-brain barrier. As such, employing different modalities of delivery is paramount to oligonucleotide targeted therapy. Ensuring a <em>truly </em>targeted delivery, however, is not only a question of drug efficacy but also one of safety. Oligonucleotides can have exaggerated pharmacologic effects; if a high dose drug is off-target, this can have serious repercussions for the patient. Side effects include complement activation, Thrombocytopenia, toxicity in the liver and kidney, as well as pro-inflammatory effects.</p>   <ul><li><a href="https://oxfordglobal.com/biologics/resources/oligonucleotide-chemistry-therapeutics-symposium-market-trends-and-industry-challenges/" target="_blank" rel="noreferrer noopener">Discover the Latest Industry Insights in Oligonucleotide Therapeutics with our Market Report for 2021</a></li><li><a href="https://oxfordglobal.com/biologics/resources/characterisation-of-therapeutic-oligonucleotides-in-early-drug-discovery/" target="_blank" rel="noreferrer noopener">What are the Analytical Challenges of Early-Stage Oligonucleotide Characterisation? </a></li><li>??<a href="https://soundcloud.com/user-30635319/why-has-the-field-of-oligonucleotides-grown-at-the-rate-it-has-over-the-past-few-years/s-qYFCwBdsTvq" target="_blank" rel="noreferrer noopener"> Listen to an Exclusive Podcast Featuring Biogen to Discover the Challenges Facing Oligonucleotide Synthesis </a></li></ul>   <p></p>   <p><strong>Efficacy:</strong> The rate and intensity of protein binding during uptake is also important. Plasma protein binding refers to the degree to which drugs attach to proteins within the blood. Minimising protein binding can optimise targeted delivery. When proteins bind too tightly, they risk sequestering the oligonucleotide. When proteins bind too loosely, the treatment is flushed out of the body. For Steve Hood, Director of Imagining Expertise Networks at GSK, the solution is a “trade-off, a balance between making sure you keep the product in the body long enough to the hit the target but making sure it's not too heavily bound that it doesn’t actually go anywhere”. Methods for improving the regulation of protein binding are currently in the early stages of development.</p>   <p><strong>Delivery:</strong> Haiyan Zhou, Principal Investigator and Associate Professor at University College London claims that “antisense drug delivery, particularly tissue and organ specific delivery, is a crucial” facing the oligonucleotide industry today. The challenge of direct lung targeting is especially prevalent. According to Punit Seth, Vice President at Ionis (now Senior Vice President at Alnylam Pharmaceuticals), “to deliver oligos to the lung via systematic circulation is not straightforward”. While the lungs receive a lot of blood flow, the conveyance of <em>oligonucleotides</em> is tricky. “It has to do with the types of tissue barriers that are present in the lungs versus those in the liver and kidney”, Seth continues. The vasculature in lungs is less porous than in other tissues like the liver and kidney which also have receptors that can bind and clear chemically modified oligonucleotides from circulation. In contrast, aerosol devices allow local delivery of ASOs and siRNA to the lungs and this mode of administration also reduces systemic exposure. This is an example of physically targeting a tissue for delivery of oligonucleotide therapeutics.</p>   <h2>RNA Splicing: The Promise of Improved Efficacy</h2>   <p>Despite these challenges, all hope is not lost as there are several exciting developments in the pipeline. Optimisation of the RNA splicing technology known as Exon-Skipping used to treat muscular diseases such as Duchenne muscular dystrophy (DMD), has been extremely promising. Research conducted into the intracellular distribution within different cell types found that because Duchenne muscle fibre is leaky, early dosage ensured good penetration. However, when target penetration was lost during later doses after these muscle fibres start healing, scientists were surprised to discover that the decrease in exposure was <em>actually</em> a direct result of improved efficacy. Regarding Exon-Skipping in DMD, UCL’s Haiyan Zhou explains that “whilst this approach will not cure the disease completely, it can slow down disease progression”. In contrast, aerosol devices allow local delivery of ASOs and siRNA to the lungs and this mode of administration also reduces systemic exposure. This is an example of physically targeting a tissue for delivery of oligonucleotide therapeutics.</p>   <h2>Precision Medicine: Optimising Patient Experience</h2>   <p>Patient experience is becoming an increasingly important part of the oligonucleotide conversation. For Charles Sinclair, Senior Principal Scientist at Bristol-Myers Squibb (now<br>Senior Director and Head of Translational Sciences at Pioneering Medicines), oncological oligonucleotide delivery <em>especially </em>requires precision attention. Sinclair explained how cancer treatment should revolve around “patient experience”. This is due to the lengthy and rigorous rehabilitation period, where patients must undergo repeat injections and demanding therapeutic regimes. Michael Keller, Senior Principal Scientist at Hoffman La Roche, attested to a similar need to treat both neurological and muscular diseases. Precision medicine paired with advances in delivery will mean “painful oligonucleotide-based injections into the brain and spinal cord on a regular basis will no longer be needed”, Keller explained. Future oligo delivery may give way to not only patient autonomy over rate and frequency of medicinal administration but also important considerations of individual variability in genes, lifestyle, and the needs of the patient.</p>   <p>Oligonucleotide therapeutics is one rapidly expanding market. Though not without challenges, the industry is working hard to optimise and overcome these hurdles. We are entering into a period of trailblazing innovation and discovery. And Moderna and Pfizer certainly set a precedent last year with their pioneering development of the nucleotide-based COVID vaccine. Word has it they are even being tipped to win the next Nobel Prize. At <a href="https://oxfordglobal.com/" target="_blank" rel="noreferrer noopener">Oxford Global</a> we firmly believe that oligonucleotides will soon become <em>the </em>forerunner of the biologics industry.  </p>   <p><em>Want to find out more about the latest market news and industry insights? Join our <a href="https://oxfordglobal.com/virtual-symposium-oligonucleotides/" target="_blank" rel="noreferrer noopener">Oligonucleotide Chemistry & Therapeutics Symposium</a> on 14th September 2022 and discover the latest in oligonucleotides chemistry, process and analytical development, therapeutics, and antisense therapy. </em></p>  <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/japanese-team-successfully-skip-abnormal-gene-in-vitro-with-antisense-oligonucleotide-for-bpan"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Japanese%20Team%20Successfully%20Skip%20Abnormal%20Gene%20In%20Vitro%20With%20Antisense%20Oligonucleotide%20for%20BPAN.png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/japanese-team-successfully-skip-abnormal-gene-in-vitro-with-antisense-oligonucleotide-for-bpan"> <h4> Japanese Team Successfully Skip Abnormal Gene In Vitro With Antisense Oligonucleotide for BPAN </h4> <div class="abstract"> Rare disease BPAN currently has no treatment options, this new research investigates whether antisense oligonucleotide therapies could be the answer to address this unmet need. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/japanese-team-successfully-skip-abnormal-gene-in-vitro-with-antisense-oligonucleotide-for-bpan" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/oligo-sequencing-methods-and-techniques"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Oligo%20Sequencing%20Technologies.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/oligo-sequencing-methods-and-techniques"> <h4> Oligo Sequencing Technologies - What Methods and Techniques Are Utilized in the Pharmaceutical Industry? </h4> <div class="abstract"> Oligo sequencing revolutionizes biologics research, ensuring accurate analysis of oligonucleotides. Biologics by Oxford Global explores methods, safety, sustainability, and future trends. Despite challenges, advancements promise exciting opportunities for scientific discovery. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/oligo-sequencing-methods-and-techniques" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/optimising-oligonucleotide-therapies-efficacy-targetability-and-precision-medicine"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999081"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999081", "legacyPageId": "hubdb-177607186815-30817717-181072999081", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "b81e17cc-61d4-47ef-8e70-78e5a84f76d7", ticks: 1732361042472, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999081", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999081", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine